A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

NCT02568306 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolism and Nutrition Disorder
Obesity

Interventions

DRUG: NNC0165-1562
DRUG: placebo

Sponsor

Novo Nordisk A/S